{"id":"silymarin-silybum-marianum","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Allergic reactions (rare)"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Silymarin, the active component of milk thistle (Silybum marianum), exerts hepatoprotective effects primarily through free radical scavenging and lipid peroxidation inhibition. It also modulates inflammatory pathways and may enhance liver cell regeneration. The mechanism involves stabilization of hepatocyte membranes and competitive inhibition of toxin binding to liver cells.","oneSentence":"Silymarin is a flavonolignan mixture that protects liver cells by acting as an antioxidant and anti-inflammatory agent, stabilizing cell membranes and inhibiting toxin uptake.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:42.890Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Liver disease and hepatotoxicity (including drug-induced liver injury)"},{"name":"Cirrhosis support"},{"name":"Hepatitis C (adjunctive)"}]},"trialDetails":[{"nctId":"NCT06477146","phase":"PHASE2","title":"Milk Thistle Clinical Trial in Pediatric NAFLD","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2024-12-19","conditions":"Non-Alcoholic Fatty Liver Disease (NAFLD)","enrollment":20},{"nctId":"NCT06882681","phase":"NA","title":"Silymarin Bioavailability Study","status":"COMPLETED","sponsor":"Isura","startDate":"2024-05-01","conditions":"Bioavailability and Pharmacokinetics","enrollment":16},{"nctId":"NCT06213857","phase":"PHASE2","title":"Beneficial Effect of Silymarin in Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-02-01","conditions":"Ulcerative Colitis","enrollment":44},{"nctId":"NCT02337634","phase":"PHASE2","title":"Milk Thistle in Pathological Gambling","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2015-01","conditions":"Pathological Gambling, Gambling Disorder","enrollment":55},{"nctId":"NCT06425705","phase":"PHASE2","title":"Impact of Silymarin Adjunct Therapy on Proteinuria in Type 2 Diabetic Patients on RAS Inhibitors","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2022-02-25","conditions":"Type 2 Diabetes Mellitus","enrollment":70},{"nctId":"NCT06277635","phase":"NA","title":"Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases","status":"UNKNOWN","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2024-02-01","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis","enrollment":72},{"nctId":"NCT04810572","phase":"NA","title":"Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-05-20","conditions":"Insulin Resistance, Inflammatory Bowel Diseases, Overweight and Obesity","enrollment":162},{"nctId":"NCT04717726","phase":"PHASE3","title":"Exercise, Milk Thistle, and Lactobacillus to Influence Plasma Bilirubin","status":"COMPLETED","sponsor":"Kyle Flack","startDate":"2021-02-24","conditions":"Obesity","enrollment":42},{"nctId":"NCT05069298","phase":"NA","title":"Effect of Silibinin(A) as a Potential Anti-obesity Agent","status":"UNKNOWN","sponsor":"Universidad Católica San Antonio de Murcia","startDate":"2023-01-12","conditions":"Overweight and Obesity, Hypercholesterolemia, Hypertriglyceridemia","enrollment":60},{"nctId":"NCT02843451","phase":"PHASE2","title":"Milk Thistle in Body Dysmorphic Disorder","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2016-10","conditions":"Body Dysmorphic Disorder","enrollment":""},{"nctId":"NCT03577587","phase":"NA","title":"Efficacy of Herbal Galactagogue Silitidil After Preterm Birth","status":"COMPLETED","sponsor":"Waldkrankenhaus Protestant Hospital, Spandau","startDate":"2017-08-14","conditions":"Breast Milk Production, Human Milk Feeding, Hypogalactia","enrollment":106},{"nctId":"NCT00915681","phase":"PHASE2","title":"Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning","status":"TERMINATED","sponsor":"Mylan Specialty, LP","startDate":"2009-11-10","conditions":"Amatoxin Poisoning, Amanita Poisoning, Mushroom Poisoning","enrollment":148},{"nctId":"NCT00412763","phase":"PHASE4","title":"Efficacy of Silymarin for Acute Hepatitis","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2003-07","conditions":"Hepatitis","enrollment":200},{"nctId":"NCT00755950","phase":"PHASE2, PHASE3","title":"Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2008-10","conditions":"Acute Hepatitis A, Acute Hepatitis B, Acute Hepatitis C","enrollment":70},{"nctId":"NCT02473913","phase":"PHASE2","title":"Milk Thistle in Trichotillomania in Children and Adults","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2015-03","conditions":"Trichotillomania, Hair Pulling Disorder","enrollment":22},{"nctId":"NCT03982849","phase":"PHASE2","title":"Comparison of Topical Silymarin With Hydroquinone in the Treatment of Melasma","status":"COMPLETED","sponsor":"Islamabad Medical and Dental College","startDate":"2019-07-15","conditions":"Melasma","enrollment":92},{"nctId":"NCT00680407","phase":"PHASE2","title":"Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Madaus Inc","startDate":"2008-04","conditions":"Non-alcoholic Steatohepatitis","enrollment":78},{"nctId":"NCT03547895","phase":"NA","title":"Management of Decompensated HCV Cirrhotic Patients","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2015-06-01","conditions":"Decompensated Cirrhosis","enrollment":80},{"nctId":"NCT01265563","phase":"PHASE2","title":"N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-01","conditions":"Diabetic Nephropathy, Proteinuria, Oxidative Stress","enrollment":108},{"nctId":"NCT00200798","phase":"","title":"An Assessment of Milk Thistle Pharmacokinetics and Drug Interactions","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2006-05","conditions":"Healthy","enrollment":32},{"nctId":"NCT03174561","phase":"NA","title":"Inuline Supplement in Patients With Irritable Bowel Syndrome","status":"UNKNOWN","sponsor":"SC Fiterman Pharma SRL","startDate":"2017-05-01","conditions":"Irritable Bowel Syndrome","enrollment":50},{"nctId":"NCT01018615","phase":"PHASE1","title":"Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-11","conditions":"Chronic Hepatitis C, Oxidative Stress","enrollment":28},{"nctId":"NCT00915200","phase":"PHASE2","title":"N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-10","conditions":"Diabetic Nephropathies, Proteinuria, Oxidative Stress","enrollment":114},{"nctId":"NCT02669641","phase":"PHASE4","title":"Complex Imaging Assessment of Steatosis","status":"UNKNOWN","sponsor":"University of Medicine and Pharmacy Craiova","startDate":"2016-01","conditions":"Fatty Liver","enrollment":50},{"nctId":"NCT02006498","phase":"PHASE2","title":"Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2012-06","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":99},{"nctId":"NCT01829178","phase":"PHASE2, PHASE3","title":"Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2013-08","conditions":"Upper GI Cancer, Cisplatin Adverse Reaction","enrollment":30},{"nctId":"NCT00487721","phase":"PHASE2","title":"The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2006-08","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT01049178","phase":"PHASE2, PHASE3","title":"Randomized Controlled Trial of Silymarin in Asthma","status":"WITHDRAWN","sponsor":"Vanderbilt University","startDate":"2010-09","conditions":"Atopic Asthma","enrollment":""},{"nctId":"NCT00055718","phase":"PHASE2","title":"Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy","status":"COMPLETED","sponsor":"Herbert Irving Comprehensive Cancer Center","startDate":"2001-11","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia","enrollment":50},{"nctId":"NCT01129570","phase":"PHASE1","title":"Siliphos in Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Abby Siegel","startDate":"2010-02","conditions":"Advanced Hepatocellular Carcinoma","enrollment":3},{"nctId":"NCT00680342","phase":"PHASE2","title":"Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment","status":"COMPLETED","sponsor":"National Center for Complementary and Integrative Health (NCCIH)","startDate":"2008-04","conditions":"Chronic Hepatitis C","enrollment":154},{"nctId":"NCT01003236","phase":"PHASE2","title":"Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2010-10","conditions":"Diabetic Nephropathy","enrollment":60},{"nctId":"NCT00246363","phase":"PHASE1, PHASE2","title":"A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C","status":"COMPLETED","sponsor":"Henry Sacks","startDate":"2005-01","conditions":"HIV Infections, Hepatitis C","enrollment":40},{"nctId":"NCT01402648","phase":"PHASE1, PHASE2","title":"Estrogen Receptor Beta Agonists (Eviendep) and Polyp Recurrence","status":"COMPLETED","sponsor":"CM&D Pharma Limited","startDate":"2009-10","conditions":"Adenocarcinoma of Colon Recurrent","enrollment":60},{"nctId":"NCT01292161","phase":"PHASE2","title":"Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2006-03","conditions":"Hepatitis C","enrollment":55},{"nctId":"NCT01001845","phase":"PHASE2","title":"Comparative Effects of Milk Thistle Extract With Vitamin-E in Hemodialysis Patients","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2009-06","conditions":"Hemodialysis, End Stage Renal Disease","enrollment":80},{"nctId":"NCT00011635","phase":"PHASE1","title":"The Effect of Milk Thistle on the Pharmacokinetics of Indinavir","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2001-02","conditions":"HIV Infection, Healthy","enrollment":20},{"nctId":"NCT00065741","phase":"PHASE1","title":"Botanical/Drug Interactions in HIV: Glucuronidation","status":"COMPLETED","sponsor":"National Center for Complementary and Integrative Health (NCCIH)","startDate":"2003-09","conditions":"HIV Seronegativity","enrollment":60},{"nctId":"NCT00030030","phase":"PHASE2","title":"Evaluating Silymarin for Chronic Hepatitis C","status":"COMPLETED","sponsor":"National Center for Complementary and Integrative Health (NCCIH)","startDate":"2000-07","conditions":"Hepatitis C, Chronic","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"PYREXIA"},{"count":3,"reaction":"DECREASED APPETITE"},{"count":3,"reaction":"DYSPNOEA"},{"count":3,"reaction":"PLATELET COUNT DECREASED"},{"count":2,"reaction":"ANAEMIA"},{"count":2,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":2,"reaction":"CHILLS"},{"count":2,"reaction":"DIABETES MELLITUS"},{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":2,"reaction":"FATIGUE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Silymarin (Silybum marianum)","genericName":"Silymarin (Silybum marianum)","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Silymarin is a flavonolignan mixture that protects liver cells by acting as an antioxidant and anti-inflammatory agent, stabilizing cell membranes and inhibiting toxin uptake. Used for Liver disease and hepatotoxicity (including drug-induced liver injury), Cirrhosis support, Hepatitis C (adjunctive).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}